Key clinical point: PET/CT provided accurate staging information on mantle cell lymphoma without the use of bone marrow biopsy.
Major finding: If greater than 38% of the voxels demonstrated an standard uptake value of less than 0.95, there was a sensitivity of 100% and a specificity of 80%.
Study details: A retrospective cohort study of 23 patients with mantle cell leukemia and 5 controls.
Disclosures: There was no external funding for the study and the researchers reported having no financial disclosures.
Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.
This Week's Must Reads
Oncologists raise access concerns about new mobile technology, Article based on interviews.
Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018
Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142
Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits
The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32
Must Reads in Lymphoma & Plasma Cell Disorders
Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262
Race and pruritus create cancer risk picture, Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.
Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.
First-line chemo-free MCL combo is durable, Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10